Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years with no upper age limit~* Competent adult patient.~* Patient affiliated to the French National Health Insurance.~* Patient with supratentorial spontaneous intracerebral hemorrhage diagnosed by CT or MRI~* Early neurological symptoms less than 24 hours~* NIHSS score on admission between 5 and 25~* Informed consent given by the patient or his legal representative~Exclusion Criteria:~* Inaugural Seizures ( at the onset of symptoms associated with intracerebral hemorrhage )~* Seizures occurring between the inclusion of the patient and the start of the EEG~* Other Intracerebral hemorrhage infratentorial , post-traumatic , related to a vascular malformation or an underlying tumor and secondarily hemorrhagic cerebral infarction~* Current antiepileptic treatment when intracerebral hemorrhage , or a history of epilepsy~* Modified Rankin Scale before intracerebral hemorrhage \> 1 (indicating a preexisting disability)~* Serious illness which can affect the prognosis within 3 months~* Severe renal impairment ( creatinine clearance \<30 ml / min)~* Pregnancy, lactation~* Known hypersensitivity to levetiracetam or other pyrrolidone derivatives , or any of the excipients.~* Untreated severe depression , psychotic disorders~* Lactose Intolerance~* Patient under measuring socio- legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lévétiracetam (Type: EXPERIMENTAL): 52 patients will be recruited over 2 years in the experimental group
- Placebo (Type: PLACEBO_COMPARATOR): 52 patients will be recruited over 2 years in the control group

Based on this trial design, predict the completion outcome and termination type (if applicable).